Progenics Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PROGENICS PHARMS INC, and when can generic versions of PROGENICS PHARMS INC drugs launch?
PROGENICS PHARMS INC has two approved drugs.
There are five US patents protecting PROGENICS PHARMS INC drugs.
There are seventy-nine patent family members on PROGENICS PHARMS INC drugs in twenty-four countries and eight supplementary protection certificates in eight countries.
Summary for Progenics Pharms Inc
International Patents: | 79 |
US Patents: | 5 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Progenics Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Progenics Pharms Inc | AZEDRA | iobenguane i-131 | SOLUTION;INTRAVENOUS | 209607-001 | Jul 30, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 11,851,407 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 9,861,713 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Progenics Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2016053025 | ⤷ Sign Up |
Portugal | 2318366 | ⤷ Sign Up |
Netherlands | 301250 | ⤷ Sign Up |
Japan | 7219497 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Progenics Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2318366 | 301250 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PIFLUFOLASTAT (18F) OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1746 20230725 |
2318366 | C20230027 00410 | Estonia | ⤷ Sign Up | PRODUCT NAME: PIFLUFOLASTAAT (18F);REG NO/DATE: EU/1/23/1746 25.07.2023 |
2318366 | 122023000060 | Germany | ⤷ Sign Up | PRODUCT NAME: PIFLUFOLASTAT (18F) ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1746 20230724 |
2318366 | LUC00323 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PIFLUFOLASTAT (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1746 20230725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.